IL1B and lung carcinoma: Interestingly, the CANTOS trial, which enrolled over 10,000 cancer-free patients, showed that those treated with canakinumab (IL-1β blocking agent) had reduced lung cancer incidence and cancer-associated mortality (7, 8).